MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Strona główna・Stock List・Cassava Sciences Inc

Cassava Sciences Inc

Closed

SectorHealthcare

2.03 -4.69

Buy Sell

Overview

Share price change

24h

Current

Min

2.02

Max

2.04

Key metrics
By Trading Economics
Income	33M -11M
Sales	840K 840K
Profit margin	-1,286.548
Employees	30
EBITDA	35M -11M

Dividends
By Dow Jones
Next Earnings	2 mar 2026

Market Stats
By TradingEconomics
Market Cap	-4.3M 142M
Previous open	6.72
Previous close	2.03

News Sentiment

By Acuity

50%

138 / 361 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

1.56 / 1.7 Support & Resistance

Cassava Sciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 gru 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 gru 2025, 23:39 UTC

Major Market Movers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

Peer Comparison

Price change

Cassava Sciences Inc Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Cassava Sciences Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.56 / 1.7Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

138 / 361 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cassava Sciences Inc

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.